You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 26, 2024

Claims for Patent: 9,566,257

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,566,257

Title:	Compositions comprising ornithine and phenylacetate or phenylbutyrate for treating hepatic encephalopathy
Abstract:	The present invention relates to use of ornithine in the manufacture of a medicament for use in combination with at least one of phenylacetate and phenylbutyrate for preventing or treating liver decompensation or hepatic encephalopathy. The invention also relates to use of at least one of phenylacetate and phenylbutyrate in the manufacture of a medicament for use in combination with ornithine for preventing or treating liver decompensation or hepatic encephalopathy.
Inventor(s):	Jalan; Rajiv (London, GB), Jalan; Kamal Nayan (Kolkata, IN)
Assignee:	UCL Business PLC (London, GB)
Application Number:	13/495,966
Patent Claims:	1. A pharmaceutical composition comprising ornithine or a physiologically acceptable salt thereof and at least one of phenylacetate or phenylbutyrate or a physiologically acceptable salt thereof, wherein the composition comprises no other amino acid, wherein the ornithine and at least one of phenylacetate or phenylbutyrate are in a weight ratio from 2:1 to 1:2, wherein the composition is formulated for oral administration. 2. The pharmaceutical composition of claim 1, wherein the ornithine and at least one of phenylacetate or phenylbutyrate are in a weight ratio of about 1:1. 3. The pharmaceutical composition of claim 1, comprising from 1 g to 50 g of ornithine and from 1 g to 50 g of phenylacetate or phenylbutyrate. 4. The pharmaceutical composition of claim 1, comprising from 5 g to 30 g of ornithine and from 5 g to 30 g of phenylacetate or phenylbutyrate. 5. The pharmaceutical composition of claim 1, comprising a physiologically acceptable salt of ornithine and a physiologically acceptable salt of at least one of phenylacetate or phenylbutyrate. 6. The pharmaceutical composition of claim 5, comprising ornithine hydrochloride and at least one of sodium phenylacetate or sodium phenylbutyrate. 7. The pharmaceutical composition of claim 1, further comprising a pharmaceutically acceptable carrier or diluent. 8. The pharmaceutical composition of claim 7, comprising sterile water. 9. A pharmaceutical composition consisting of ornithine or a physiologically acceptable salt thereof, at least one of phenylacetate or phenylbutyrate or a physiologically acceptable salt thereof, and a pharmaceutically acceptable carrier, wherein the composition is formulated for oral administration.

Details for Patent 9,566,257

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006	⤷ Try a Trial	2024-11-26
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.